Cardiac Biomarker Research Reagents

Cardiac biomarkers are circulating proteins released during myocardial injury, hemodynamic stress, or pathological remodeling. High-sensitivity cardiac troponin (hs-cTn) is the diagnostic standard for acute myocardial infarction; natriuretic peptides (BNP/NT-proBNP) guide heart failure management; and emerging markers such as sST2 and Galectin-3 provide independent prognostic information for fibrosis and adverse cardiac remodeling. Developing next-generation immunoassays for these targets requires rigorously characterized antibody pairs and calibrator-grade recombinant proteins.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key cardiac biomarker targets. Matched antibody pairs are available for sandwich immunoassay development. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Myocardial Injury Markers

Cardiac Troponin I (cTnI) — The preferred biomarker for acute myocardial infarction diagnosis per ESC/ACC guidelines. cTnI is released from damaged cardiomyocytes within 2–4 hours of injury. High-sensitivity cTnI assays require antibody pairs targeting distinct epitopes on the stable central fragment (amino acids 30–110) to avoid interference from degradation products.
→ Browse Troponin I antibodies & proteins

Cardiac Troponin T (cTnT) — Complementary myocardial injury marker with a longer detection window than cTnI. cTnT release kinetics reflect both acute necrosis and chronic myocardial stress. Recombinant cTnT proteins serve as calibrators and positive controls in assay development.
→ Browse Troponin T antibodies & proteins

CK-MB (Creatine Kinase-MB) — Historical cardiac injury marker still used in reinfarction detection due to its faster clearance kinetics compared to troponin. CK-MB rises within 3–6 hours and normalizes within 48–72 hours, enabling detection of recurrent ischemic events.
→ Browse CK-MB antibodies & proteins

Heart Failure Biomarkers

BNP / NT-proBNP — B-type natriuretic peptides are released from ventricular cardiomyocytes in response to volume overload and wall stress. BNP and NT-proBNP are guideline-recommended biomarkers for heart failure diagnosis, severity grading, and treatment response monitoring. Recombinant proteins serve as immunoassay calibrators; matched antibody pairs support ELISA and lateral flow development.
→ Browse BNP / NT-proBNP antibodies & proteins

sST2 (Soluble IL-33 Receptor / IL1RL1) — Soluble ST2 is a prognostic biomarker for myocardial fibrosis and adverse remodeling, independent of and complementary to natriuretic peptides. FDA-cleared as a prognostic marker in chronic heart failure. Elevated sST2 predicts mortality and hospitalization risk regardless of ejection fraction.
→ Browse sST2 antibodies & proteins

Galectin-3 (LGALS3) — Secreted lectin that drives cardiac fibroblast activation and extracellular matrix deposition. Elevated Galectin-3 levels predict incident heart failure in the general population and adverse outcomes in established heart failure. FDA-cleared as an adjunctive prognostic marker.
→ Browse Galectin-3 antibodies & proteins

References

1. Thygesen K, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-269. DOI

2. Mueller C, et al. Heart Failure Association of the ESC practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-731. DOI

3. Januzzi JL, et al. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol. 2015;115(7 Suppl):70B-75B. DOI

4. de Boer RA, et al. Galectin-3 in heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2014;16(2):133-142. DOI